CNS Phase 3 Readout Calendar

Industry-sponsored cns trials with primary completion in the next 12 months or last 12 months.

Data last updated September 20, 2026 · source: ClinicalTrials.gov

Pro feature

All areas Oncology Immunology MetabolicCNSCardiovascular Rare Disease Respiratory Infectious Disease Ophthalmology Musculoskeletal Dermatology Renal

Next 6 months

Next 12 months

Results posted

302

Phase 3 CNS

What you can answer with this page

A confidence-graded calendar of every industry Phase 3 cns trial reading out in the next 12 months — with a per-row staleness flag so you know which completion dates are still credible.

What cns trials are reading out soon?

The "upcoming" section shows industry-sponsored Phase 3 cns trials with primary completion ahead, soonest first, each graded by how credible that date is.

Which cns trials have already read out?

The "recently read out" section shows Phase 3 cns trials whose primary endpoint completed in the last 12 months — results posted, or completed and awaiting topline.

How are these readout dates sourced?

Every date is the ClinicalTrials.gov primary completion date — the only public, structured signal. We grade each by whether it is actual or sponsor-estimated, and by how recently the trial record was updated.

Where can I see readouts for other therapeutic areas?

The full cross-area calendar is on the main readout calendar; this page is the CNS slice of it.

Recently read-out results are free; the upcoming calendar shows a free preview. See the full cross-area calendar → or the CNS landscape →

Recently read out & awaiting topline — CNS

· 16

Phase 3 cns trials whose primary endpoint completed in the last 12 months — results posted, or completed and awaiting topline. Most recent first.

Sponsor	Trial / Asset	Indication	Status	Primary completion	Confidence	NCT
Novartis Pharmaceuticals	Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis Asset: Fingolimod	Multiple Sclerosis (MS)	Active Not Recruiting	Q1 2026 2026-03-25	Completed · awaiting Updated 6mo ago	NCT04926818
Tasly Pharmaceutical Group Co., Ltd	A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis Asset: pimavanserin tartrate	Parkinson's Disease Psychosis	Completed	Q1 2026 2026-02-01	Completed · awaiting Updated 7mo ago	NCT06068465
Novartis Pharmaceuticals	Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab Asset: Ofatumumab approved dose	Relapsing Multiple Sclerosis (RMS)	Active Not Recruiting	Q1 2026 2026-01-28	Completed · awaiting Updated 5mo ago	NCT06869785
Hoffmann-La Roche	A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) Asset: Fenebrutinib	Relapsing Multiple Sclerosis	Active Not Recruiting	Q1 2026 2026-01-27	Completed · awaiting Updated 7mo ago	NCT04586010
Lipocine Inc.	A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD Asset: LPCN 1154A	Depression, Postpartum +5	Completed	Q1 2026 2026-01-16	Completed · awaiting Updated 7mo ago	NCT06979544
Eli Lilly and Company	A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine Asset: Galcanezumab	Chronic Migraine	Active Not Recruiting	Q4 2025 2025-12-10	Completed · awaiting Updated 7mo ago	NCT04616326
AbbVie	Open-label Trial in Parkinson's Disease (PD) Asset: Tavapadon	Parkinson Disease	Completed	Q4 2025 2025-12-01	Completed · awaiting Updated 9mo ago	NCT04760769
Amgen	Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine Asset: Erenumab Dose 1	Migraine	Active Not Recruiting	Q4 2025 2025-11-19	Completed · awaiting Updated 9mo ago	NCT03836040
Eli Lilly and Company	A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine Asset: Galcanezumab	Episodic Migraine	Active Not Recruiting	Q4 2025 2025-11-14	Completed · awaiting Updated 8mo ago	NCT03432286
Sanofi	Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS) Asset: Tolebrutinib	Primary Progressive Multiple Sclerosis	Completed	Q4 2025 2025-11-14	Completed · awaiting Updated 8mo ago	NCT04458051
Novartis Pharmaceuticals	Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS Asset: Ofatumumab	Multiple Sclerosis	Completed	Q4 2025 2025-11-04	Completed · awaiting Updated 7mo ago	NCT04788615
VistaGen Therapeutics, Inc.	Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3) Asset: Fasedienol Nasal Spray	Social Anxiety Disorder	Active Not Recruiting	Q4 2025 2025-10-31	Completed · awaiting Updated 10mo ago	NCT06358651
Biohaven Pharmaceuticals, Inc.	Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder Asset: Troriluzole	Obsessive-Compulsive Disorder	Completed	Q4 2025 2025-10-27	Completed · awaiting Updated 8mo ago	NCT04641143
AbbVie	A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine Asset: Atogepant 60 mg	Episodic Migraine +1	Completed	Q4 2025 2025-10-20	Completed · awaiting Updated 9mo ago	NCT04686136
AbbVie	Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder Asset: Cariprazine Flexible Dose	Schizophrenia +2	Completed	Q4 2025 2025-10-06	Completed · awaiting Updated 11mo ago	NCT04578756
Otsuka Pharmaceutical Development …	A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder Asset: SEP-363856	Generalized Anxiety Disorder	Completed	Q3 2025 2025-09-26	Completed · awaiting Updated 11mo ago	NCT05729373

Upcoming cns readouts — next 12 months

· 72

Industry Phase 3 cns trials with primary completion ahead, soonest first — confidence-graded by date type and CT.gov staleness.

Sponsor	Trial / Asset	Indication	Status	Primary completion	Confidence	NCT
Karuna Therapeutics, Inc., a Brist…	A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) Asset: KarXT	Alzheimer Disease	Recruiting	Q3 2026 2026-09-21 (est.)	Estimated · fresh Updated 6mo ago	NCT06585787
Alkermes, Inc.	Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder Asset: OLZ/SAM	Schizophrenia +1	Recruiting	Q3 2026 2026-09 (est.)	Estimated · aging Updated 7mo ago	NCT05303064
argenx	A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy Asset: Empasiprubart	Multifocal Motor Neuropathy (MMN) +1	Active Not Recruiting	Q3 2026 2026-09 (est.)	Estimated · fresh Updated 6mo ago	NCT06742190
ScandiBio Therapeutics AB	Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease Asset: Combined metabolic activators	Alzheimer Disease	Recruiting	Q3 2026 2026-09 (est.)	Estimated · aging Updated 7mo ago	NCT07062198
Qilu Pharmaceutical Co., Ltd.	GM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast Cancer Asset: GM1	Chemotherapy-induced Peripheral Neuropathy (CIPN)	Recruiting	Q3 2026 2026-09 (est.)	Estimated · stale Updated 13mo ago	NCT06994507
Intra-Cellular Therapies, Inc.	Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Asset: Lumateperone	Major Depressive Disorder	Recruiting	Q3 2026 2026-09 (est.)	Estimated · stale Updated 15mo ago	NCT05850689
CSPC Ouyi Pharmaceutical Co., Ltd.	A Trial of Dextromethorphan and Bupropion Sustained-Release Tablets in Patients With Major Depressive Disorder Asset: Dextromethorphan and Bupropion Sustained-Release Tablets	Major Depressive Disorder (MDD)	Recruiting	Q3 2026 2026-09-30 (est.)	Estimated · stale Updated 16mo ago	NCT06958692
SyneuRx International (Taiwan) Corp	An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults Asset: NaBen®	Refractory Schizophrenia	Recruiting	Q3 2026 2026-09-30 (est.)	Estimated · stale Updated 60mo ago	NCT03094429
Karuna Therapeutics, Inc., a Brist…	A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1) Asset: KarXT	Psychosis Associated With Alzheimer's Disease	Recruiting	Q4 2026 2026-10-05 (est.)	Estimated · fresh Updated 5mo ago	NCT05511363
Pfizer	A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine Asset: Rimegepant	Migraine	Active Not Recruiting	Q4 2026 2026-10-08 (est.)	Estimated · fresh Updated 5mo ago	NCT06616194
Sandoz	Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis Asset: CYB704	Relapsing Multiple Sclerosis	Active Not Recruiting	Q4 2026 2026-10-14 (est.)	Estimated · aging Updated 7mo ago	NCT06847724
Otsuka Pharmaceutical Development …	A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia Asset: SEP-363856	Schizophrenia	Recruiting	Q4 2026 2026-10-20 (est.)	Estimated · fresh Updated 5mo ago	NCT06894212
Senseye, Inc.	REVEAL Study - Diagnostic Testing for PTSD Using the Senseye Diagnostic Tool	PTSD - Post Traumatic Stress Disorder	Recruiting	Q4 2026 2026-10 (est.)	Estimated · fresh Updated 5mo ago	NCT07280065
Actinogen Medical	Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease Asset: Xanamem	Dementia Moderate +2	Active Not Recruiting	Q4 2026 2026-10 (est.)	Estimated · fresh Updated 5mo ago	NCT06125951
Bristol-Myers Squibb	A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2) Asset: KarXT	Bipolar Disorder Type I With Mania or Mania With Mixed Features	Recruiting	Q4 2026 2026-11-02 (est.)	Estimated · fresh Updated 5mo ago	NCT06951711
Hoffmann-La Roche	A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis Asset: Ocrelizumab	Progressive Multiple Sclerosis (PMS)	Active Not Recruiting	Q4 2026 2026-11-12 (est.)	Estimated · aging Updated 8mo ago	NCT03523858
Pfizer	A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine Asset: Rimegepant	Menstrual Migraine	Recruiting	Q4 2026 2026-11-29 (est.)	Estimated · fresh Updated 5mo ago	NCT06641466
Definium Therapeutics US, Inc.	A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama) Asset: DT120	Generalized Anxiety Disorder	Active Not Recruiting	Q4 2026 2026-11 (est.)	Estimated · fresh Updated 6mo ago	NCT06809595
SK Life Science, Inc.	Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures Asset: Xcopri	Partial Epilepsy	Active Not Recruiting	Q4 2026 2026-11 (est.)	Estimated · fresh Updated 6mo ago	NCT05067634
Definium Therapeutics US, Inc.	A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge) Asset: DT120	Major Depressive Disorder	Active Not Recruiting	Q4 2026 2026-11 (est.)	Estimated · fresh Updated 6mo ago	NCT06941844
Immunic AG	Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis Asset: IMU-838 tablets	Multiple Sclerosis	Active Not Recruiting	Q4 2026 2026-11 (est.)	Estimated · aging Updated 7mo ago	NCT05134441
Immunic AG	Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis Asset: IMU-838 tablets	Multiple Sclerosis, Relapsing-Remitting	Active Not Recruiting	Q4 2026 2026-11 (est.)	Estimated · aging Updated 7mo ago	NCT05201638
JYAMS PET Research & Development L…	Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function Asset: [18F]-APN-1607	Subjects With Mild Cognitive Impairment (MCI) of AD, Alzheimer's Disease (AD) Dementia	Recruiting	Q4 2026 2026-12-01 (est.)	Estimated · aging Updated 7mo ago	NCT07422857
Karuna Therapeutics, Inc., a Brist…	A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2) Asset: KarXT	Psychosis Associated With Alzheimer's Disease	Recruiting	Q4 2026 2026-12-09 (est.)	Estimated · fresh Updated 5mo ago	NCT06126224
Gedeon Richter Plc.	Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia Asset: Cariprazine	Schizophrenia	Recruiting	Q4 2026 2026-12-15 (est.)	Estimated · aging Updated 11mo ago	NCT03817502
Sanofi	Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis Asset: Frexalimab	Multiple Sclerosis	Active Not Recruiting	Q4 2026 2026-12-23 (est.)	Estimated · aging Updated 7mo ago	NCT06141486
Janssen Research & Development, LLC	Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms Asset: Seltorexant	Depressive Disorder, Major	Recruiting	Q4 2026 2026-12-30 (est.)	Estimated · fresh Updated 5mo ago	NCT06559306
Biohaven Therapeutics Ltd.	A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy Asset: BHV-7000	Focal Epilepsy	Recruiting	Q4 2026 2026-12 (est.)	Estimated · fresh Updated 6mo ago	NCT06132893
Vanda Pharmaceuticals	Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder Asset: VQW-765	Social Anxiety Disorder (SAD)	Active Not Recruiting	Q4 2026 2026-12 (est.)	Estimated · fresh Updated 5mo ago	NCT07221578
Tasly Pharmaceutical Group Co., Ltd	A Study of the Effectiveness and Safety of JS1-1-01 Tablet in Patients With Moderate to Severe Depression Asset: Placebo group	Depression	Not Yet Recruiting	Q4 2026 2026-12-31 (est.)	Estimated · fresh Updated 5mo ago	NCT07485595
TG Therapeutics, Inc.	A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS) Asset: Ublituximab	Relapsing Multiple Sclerosis	Active Not Recruiting	Q4 2026 2026-12-31 (est.)	Estimated · fresh Updated 6mo ago	NCT07211633
Suven Life Sciences Limited	Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type Asset: Masupirdine 50 mg	Agitation +1	Active Not Recruiting	Q4 2026 2026-12 (est.)	Estimated · aging Updated 8mo ago	NCT05397639
NeuroRx, Inc.	A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial Asset: NRX-101	Treatment Resistant Depression +1	Not Yet Recruiting	Q4 2026 2026-12-31 (est.)	Estimated · aging Updated 10mo ago	NCT07227103
Amgen	Comparison Between ABP 692 and Ocrevus® (Ocrelizumab) Asset: Ocrelizumab (US)	Relapsing-remitting Multiple Sclerosis (RRMS)	Active Not Recruiting	Q1 2027 2027-01-15 (est.)	Estimated · fresh Updated 5mo ago	NCT06700343
Praxis Precision Medicines	Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures Asset: 40 mg/day vormatrogine for 12 weeks	Focal Epilepsy	Active Not Recruiting	Q1 2027 2027-01 (est.)	Estimated · fresh Updated 6mo ago	NCT07505004
Xenon Pharmaceuticals Inc.	An Open-Label Study of Azetukalner in Major Depressive Disorder Asset: Azetukalner	Major Depressive Disorder	Enrolling By Invitation	Q1 2027 2027-01 (est.)	Estimated · aging Updated 8mo ago	NCT06922110
Ono Pharmaceutical Co., Ltd.	ONO-2017 Study Japanese Patients With Primary Generalized Tonic Clonic Seizures. Asset: Cenobamate	Epilepsy, Generalized	Recruiting	Q1 2027 2027-01-31 (est.)	Estimated · stale Updated 15mo ago	NCT06579573
Jiangsu HengRui Medicine Co., Ltd.	A Study to Evaluate the Efficacy and Safety of HRG2010 in Parkinson's Disease With Motor Fluctuations Asset: HRG2010; Sustained-release Carbidopa/Levodopa administered placebo	Parkinson's Disease	Completed	Q1 2027 2027-01-31 (est.)	Estimated · stale Updated 17mo ago	NCT06596876
AbbVie	Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine Asset: Atogepant	Menstrual Migraine (MM)	Active Not Recruiting	Q1 2027 2027-02 (est.)	Estimated · aging Updated 7mo ago	NCT06806293
Celltrion	A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis Asset: CT-P53	Relapsing-remitting Multiple Sclerosis	Recruiting	Q1 2027 2027-02 (est.)	Estimated · stale Updated 28mo ago	NCT05906992
Cybin IRL Limited	A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder Asset: CYB003	Major Depressive Disorder (MDD) +5	Recruiting	Q1 2027 2027-03-18 (est.)	Estimated · fresh Updated 5mo ago	NCT06793397
AbbVie	A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder. Asset: Cariprazine	Depression +1	Recruiting	Q1 2027 2027-03 (est.)	Estimated · fresh Updated 6mo ago	NCT04777357
Merz Therapeutics GmbH	A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine Asset: Xeomin	Episodic Migraine	Recruiting	Q1 2027 2027-03 (est.)	Estimated · fresh Updated 5mo ago	NCT07018700
BlueRock Therapeutics	A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease Asset: bemdaneprocel	Parkinsons Disease (PD)	Recruiting	Q1 2027 2027-03 (est.)	Estimated · fresh Updated 6mo ago	NCT06944522
Intra-Cellular Therapies, Inc.	Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients Asset: Lumateperone high dose	Irritability Associated With Autism Spectrum Disorder	Recruiting	Q1 2027 2027-03 (est.)	Estimated · stale Updated 14mo ago	NCT06706674
Intra-Cellular Therapies, Inc.	Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients Asset: Lumateperone high dose	Irritability Associated With Autism Spectrum Disorder	Recruiting	Q1 2027 2027-03 (est.)	Estimated · stale Updated 15mo ago	NCT06690398
Shenzhen Sciencare Medical Industr…	Evaluate the Efficacy and Safety of Naltrexone Hydrochloride Implant in Patients With Alcohol Use Disorder Asset: Naltrexone	Alcohol Use Disorder (AUD)	Not Yet Recruiting	Q2 2027 2027-04-01 (est.)	Estimated · aging Updated 7mo ago	NCT07433413
MediciNova	Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS Asset: MN-166	Amyotrophic Lateral Sclerosis	Active Not Recruiting	Q2 2027 2027-04 (est.)	Estimated · aging Updated 7mo ago	NCT04057898
Intra-Cellular Therapies, Inc.	Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients Asset: Lumateperone	Bipolar Depression	Recruiting	Q2 2027 2027-04 (est.)	Estimated · stale Updated 14mo ago	NCT06372964
Sanofi	Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis Asset: Frexalimab	Multiple Sclerosis	Active Not Recruiting	Q2 2027 2027-05-06 (est.)	Estimated · fresh Updated 5mo ago	NCT06141473
Biogen	A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis Asset: BIIB017 (peginterferon beta-1a)	Multiple Sclerosis, Relapsing-Remitting	Active Not Recruiting	Q2 2027 2027-05-20 (est.)	Estimated · aging Updated 12mo ago	NCT03958877
Skyhawk Therapeutics, Inc.	Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With Huntington's Disease Asset: SKY-0515	Huntington Disease +1	Active Not Recruiting	Q2 2027 2027-05 (est.)	Estimated · fresh Updated 5mo ago	NCT06873334
Xenon Pharmaceuticals Inc.	A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) Asset: Azetukalner	Major Depressive Disorder	Recruiting	Q2 2027 2027-05 (est.)	Estimated · fresh Updated 5mo ago	NCT07076407
Bigespas LTD	Efficacy and Safety of DMB-I (INN: Latrepirdine) in Patients With Alzheimer Type Dementia Asset: DMB-I (INN: Latrepirdine)	Alzheimer Type Dementia	Recruiting	Q2 2027 2027-05 (est.)	Estimated · aging Updated 9mo ago	NCT07251023
Bristol-Myers Squibb	A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine Asset: Xanomeline/Trospium Chloride	Mania +1	Recruiting	Q2 2027 2027-06-28 (est.)	Estimated · fresh Updated 5mo ago	NCT07140913
Psicofarma, S.A. De C.V.	Clinical Trial to Evaluate the Efficacy and Safety of the Aurora® Digital Medical Device in Adult Patients With Moderate to Severe Generalized Anxiety Disorder Asset: Pharmacological conventional treatment	General Anxiety Disorder	Recruiting	Q2 2027 2027-06-29 (est.)	Estimated · fresh Updated 6mo ago	NCT07477990
AbbVie	Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine Asset: Ubrogepant	Migraine	Active Not Recruiting	Q2 2027 2027-06 (est.)	Estimated · aging Updated 10mo ago	NCT06417775
LB Pharmaceuticals Inc.	Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia Asset: LB-102 (50 mg tablet)	Schizophrenia	Recruiting	Q2 2027 2027-06 (est.)	Estimated · fresh Updated 5mo ago	NCT07363577
Lantheus Biosciences Ltd.	[18F]PI-2620 Phase 3 Histopathological Study Asset: [18F]PI-2620	Alzheimer Disease	Recruiting	Q2 2027 2027-06 (est.)	Estimated · aging Updated 8mo ago	NCT05641688
Gipfel Life Sciences GmbH	This Study Evaluates the Safety, Target Engagement, and Preliminary Efficacy of Galunisertib (TGF-βR1/ALK5 Inhibitor)Combined With Nerandomilast (PDE4 Inhibitor) in GREM2-positive ALS, a Biomarker-defined Subgroup Hypothesized to Reflect Heightened TGF-β/SMAD-driven Astrocytic and Fibrotic Signaling Asset: Galunisertib + Nerandomilast Combination	ALS (Amyotrophic Lateral Sclerosis)	Not Yet Recruiting	Q2 2027 2027-06-30 (est.)	Estimated · aging Updated 8mo ago	NCT07321860
Vericel Corporation	A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee Asset: MACI	Chondral Defect +3	Recruiting	Q2 2027 2027-06 (est.)	Estimated · stale Updated 22mo ago	NCT03588975
H. Lundbeck A/S	A Study of Eptinezumab in Pediatric Participants With Episodic Migraine Asset: Eptinezumab	Episodic Migraine	Recruiting	Q3 2027 2027-07-06 (est.)	Estimated · fresh Updated 6mo ago	NCT05897320
Sanofi	Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis Asset: Frexalimab	Multiple Sclerosis	Recruiting	Q3 2027 2027-07-15 (est.)	Estimated · fresh Updated 5mo ago	NCT07325292
Neurocrine Biosciences	NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) Asset: NBI-1065845	Major Depressive Disorder	Recruiting	Q3 2027 2027-07 (est.)	Estimated · fresh Updated 5mo ago	NCT06963021
Neurocrine Biosciences	NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) Asset: NBI-1065845	Major Depressive Disorder	Recruiting	Q3 2027 2027-07 (est.)	Estimated · aging Updated 10mo ago	NCT06911112
Neurocrine Biosciences	Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) Asset: NBI-1065845	Major Depressive Disorder	Recruiting	Q3 2027 2027-07 (est.)	Estimated · aging Updated 11mo ago	NCT06786624
IntraBio Inc	Pivotal Study of N-acetyl-L-leucine for CACNA1A Asset: N-Acetyl-L-Leucine	CACNA1A +3	Recruiting	Q3 2027 2027-08-01 (est.)	Estimated · fresh Updated 6mo ago	NCT07221292
Biogen	A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation Asset: Tofersen	Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation	Active Not Recruiting	Q3 2027 2027-08-07 (est.)	Estimated · fresh Updated 6mo ago	NCT04856982
Biohaven Therapeutics Ltd.	A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease Asset: BHV-8000 10mg	Parkinson Disease	Recruiting	Q3 2027 2027-08 (est.)	Estimated · aging Updated 8mo ago	NCT06976268
Otsuka Pharmaceutical Co., Ltd.	A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD Asset: EB-1020 (Centanafadine) low dose	Attention-Deficit Hyperactivity Disorder(ADHD)	Recruiting	Q3 2027 2027-08 (est.)	Estimated · aging Updated 9mo ago	NCT07086313
Otsuka Pharmaceutical Co., Ltd.	A Long-term Trial of EB-1020 in Pediatric Patients With ADHD Asset: EB-1020 (Centanafadine) low dose	Attention-Deficit Hyperactivity Disorder(ADHD)	Recruiting	Q3 2027 2027-08 (est.)	Estimated · aging Updated 9mo ago	NCT07087327
Karuna Therapeutics, Inc., a Brist…	Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) Asset: KarXT	Psychosis Associated With Alzheimer's Disease	Recruiting	Q3 2027 2027-09-07 (est.)	Estimated · fresh Updated 5mo ago	NCT05980949

Unlock 64 more cns readouts · plus filters on the full calendar

Upgrade to Pro

About this calendar

Dates anchor on the ClinicalTrials.gov primary completion date — the only public, structured signal — and are graded by date type (actual vs sponsor-estimated) and how recently the record was updated. Sponsor-estimated dates can slip silently, so treat each as a current target rather than a guarantee. See the full readout calendar for all areas and filters.